01 Advancements in Diagnostic and Treatment Technologies Technological advancement is a major factor driving the growth of the global keratoconus treatment market. The growing availability of improved imaging tools, such as corneal cross-linking systems and corneal tomography, are widely used in diagnosing and managing keratoconus. For instance, ZEISS’s ATLAS 500 is a state-of-the-art solution for capturing detailed corneal properties with high-resolution images and videos. This technology enhances diagnostic precision, enabling eye care professionals to assess and monitor conditions such as keratoconus and other corneal irregularities with improved accuracy and reliability. Therefore, technological advancements, such as improved imaging tools and innovative systems like ZEISS’s ATLAS 500, are revolutionizing keratoconus diagnosis and management. These innovations drive market growth by enabling earlier detection and more effective treatment strategies.
02 Personalized and Customized Solutions The development of customized contact lenses, such as scleral and hybrid lenses, and tailored surgical options like Intacs and topography-guided treatments cater to individual patient needs, enhancing the efficacy of keratoconus management. For instance, Essilor offers customized contact lenses such as eSCone, eBCone, AdvantageK, eCCone, and Aspheric Con for keratoconus management. The eSCone has an aspheric finish cone design with a base curve of 4.50 - 12.00 and is available in power of +25.00 to -37.50. Such personalized and customized solutions expand the range of effective treatment options, improving patient outcomes and increasing the quality of life for people suffering from keratoconus.
April 2026 The U.S. Centers for Medicare & Medicaid Services (CMS) assigned Glaukos' Epioxa® a permanent J-code (J2782), supporting standardized reimbursement and broader commercial adoption of the first FDA-approved epithelium-on corneal cross-linking therapy for keratoconus.
March 2026 Glaukos commercially launched Epioxa® in the United States, making the first FDA-approved, minimally invasive epithelium-on corneal collagen cross-linking therapy available for patients with progressive keratoconus.
October 2025 Glaukos received U.S. FDA approval for Epioxa® (Epioxa HD/Epioxa), the first incision-free, epithelium-on corneal cross-linking treatment for keratoconus. The therapy eliminates the need for corneal epithelium removal, reducing patient discomfort and recovery time compared with conventional epithelium-off procedures.